Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at St. Vincent Carmel
Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at St. Vincent Carmel
The purpose of this study is to assess anti-factor Xa concentrations in patients given
 prophylactic enoxaparin after bariatric surgery.
FDA-approved enoxaparin dosing for venous thromboembolism (VTE) prophylaxis is a fixed-dose
 regimen irrespective of body mass index (BMI) or actual body weight (ABW). Clinical trials
 suggest that dosing may be inadequate for obese patients. We plan to assess anti-factor-Xa
 concentrations in patients who received prophylactic enoxaparin after bariatric surgery.

 This prospective study will examine 150 anti-factor Xa concentrations from patients 18 years
 or older undergoing primary Roux-en-Y gastric bypass surgery at St. Vincent Carmel Bariatric
 Center of Excellence. Patients receive varying prophylactic enoxaparin regimens at the
 surgeon's discretion. Anti-factor-Xa concentrations are obtained at steady state.
Inclusion Criteria:

 -  Patients 18 years and older undergoing primary roux-en-Y gastric bypass surgery at St.
 Vincent Carmel Bariatric Center of Excellence

 Exclusion Criteria:

 -  Receiving anticoagulation therapy prior to surgery (i.e. warfarin)

 -  Did not receive enoxaparin after surgery